1,000
Participants
Start Date
July 21, 2025
Primary Completion Date
July 14, 2033
Study Completion Date
July 14, 2033
Patritumab deruxtecan
Administered via intravenous (IV) infusion
Paclitaxel
Administered via IV infusion
Nab-paclitaxel
Administered via IV infusion
Capecitabine
Administered via oral tablets
Liposomal doxorubicin
Administered via IV infusion
Trastuzumab deruxtecan
Administered via IV infusion
RECRUITING
MacKay Memorial Hospital ( Site 2802), Taipei
RECRUITING
Clinical Research Alliance ( Site 0009), Westbury
RECRUITING
Seoul National University Bundang Hospital ( Site 2703), Seongnam
RECRUITING
Cancer Care Associates Of York ( Site 0063), York
RECRUITING
Comprehensive Hematology Oncology ( Site 0060), St. Petersburg
RECRUITING
TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0020), Cincinnati
RECRUITING
Circuit Clinical/SSM Health Dean Medical Group ( Site 0039), Madison
RECRUITING
Oncology Consultants P.A. ( Site 0061), Houston
RECRUITING
St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021), Grand Junction
RECRUITING
Los Angeles Hematology Oncology Medical Group ( Site 0026), Los Angeles
RECRUITING
National Cheng Kung University Hospital ( Site 2804), Tainan City
RECRUITING
Rambam Health Care Campus ( Site 1401), Haifa
RECRUITING
Sheba Medical Center ( Site 1400), Ramat Gan
RECRUITING
Hadassah Medical Center ( Site 1404), Jerusalem
RECRUITING
National Hospital Organization Hokkaido Cancer Center ( Site 3215), Sapporo
RECRUITING
Chiba Cancer Center ( Site 3203), Chiba
RECRUITING
Gangnam Severance Hospital, Yonsei University Health System ( Site 2701), Gangnam-gu
RECRUITING
Seoul National University Hospital ( Site 2702), Jongno-Gu
RECRUITING
Severance Hospital Yonsei University Health System ( Site 2700), Seoul
Collaborators (1)
Daiichi Sankyo
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY